Valerio Therapeutics Société anonyme Valuation

Is ALVIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALVIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALVIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALVIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALVIO?

Key metric: As ALVIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALVIO. This is calculated by dividing ALVIO's market cap by their current revenue.
What is ALVIO's PS Ratio?
PS Ratio	6.5x
Sales	€1.89m
Market Cap	€12.27m

ALVIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11.4x
Enterprise Value/EBITDA	-1.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALVIO's PS Ratio compare to its peers?

The above table shows the PS ratio for ALVIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.8x
PHXM PHAXIAM Therapeutics	8x	92.4%	€17.2m
ALCOX Nicox	3.2x	-9.3%	€15.1m
ALOPM Oncodesign Precision Medicine Société anonyme	13.8x	48.2%	€18.4m
POXEL Poxel	6.1x	n/a	€12.2m
ALVIO Valerio Therapeutics Société anonyme	6.5x	n/a	€12.3m

Price-To-Sales vs Peers: ALVIO is good value based on its Price-To-Sales Ratio (6.5x) compared to the peer average (7.8x).

Price to Sales Ratio vs Industry

How does ALVIO's PS Ratio compare vs other companies in the FR Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
ALGEN genOway Société anonyme	1.2x	n/a	US$35.42m
LYS Lysogene	0.4x	n/a	US$5.42m
ALINT IntegraGen	0.2x	n/a	US$3.14m
GV Genomic Vision Société Anonyme	0.4x	n/a	US$746.33k

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ALVIO is expensive based on its Price-To-Sales Ratio (6.5x) compared to the French Biotechs industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is ALVIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALVIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALVIO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Euroapi

€325.2m

Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use.

EAPI

€3.42

-2.9%

-37.5%

Sanofi

€113.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€90.87

-3.7%

5.4%

Theranexus Société Anonyme

€4.0m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.51

0.4%

-57.1%